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ABSTRACT
Objectives: To estimate the cost-effectiveness of switching patients with
poorly controlled type 2 diabetes mellitus from human insulin (HI) to
biphasic insulin aspart 30 (BIAsp 30) in South Korea.
Methods: A published and validated diabetes computer simulation
model (the IMS CORE Diabetes Model) was used to evaluate the
long-term clinical and economic outcomes associated with switching to
BIAsp 30, using treatment effects from the South Korean subgroup of
the Physician’s Routine Evaluation of Safety and Efﬁcacy of
NovoMix® 30 Therapy study and cost data collected through primary
research. Outcomes included life expectancy, quality-adjusted life
expectancy, incidence of complications, direct medical costs, and cost-
effectiveness. Analyses were performed from a third-party payer perspec-
tive over a 30-year time horizon. Future costs and clinical beneﬁts
were discounted at 5% per annum. Extensive sensitivity analyses were
performed.
Results: Switching patients uncontrolled on HI to BIAsp 30 was projected
to increase discounted mean life expectancy by 0.15  0.18 years per
patient (8.62  0.13 years vs. 8.47  0.13 years) and improve discounted
mean quality-adjusted life expectancy by 0.30  0.12 quality-adjusted
life-years (QALYs) per patient (5.68  0.09 QALYs vs. 5.38  0.09
QALYs). Conversion to BIAsp 30 was associated with a mean increase in
direct costs of South Korean Won (KRW) 1,777,323  359,209 over
patient lifetimes. BIAsp 30 was associated with an incremental cost-
effectiveness ratio of KRW5,916,758 per QALY gained versus HI.
Conclusion: Switching patients uncontrolled on HI to BIAsp 30 was pro-
jected to improve life expectancy and quality-adjusted life expectancy.
This analysis suggests that BIAsp 30 could be a cost-effective treatment
option in type 2 diabetes patients poorly controlled on HI in South Korea.
Keywords: biphasic insulin aspart 30, cost-effectiveness, modeling, South
Korea, type 2 diabetes.
Introduction
Type 2 diabetes is a leading cause of morbidity and mortality
worldwide. The World Health Organization estimates that dia-
betes is responsible for approximately 5% of all deaths world-
wide, with global diabetes-related mortality predicted to increase
by more than 50% over the next 10 years [1]. The prevention,
management, and treatment of type 2 diabetes and diabetes-
related complications place a substantial burden on health-care
systems and present a considerable public health challenge to
national health-care systems, particularly in middle-income
countries experiencing proportionally higher growth in noncom-
municable diseases compared with the Organisation for Eco-
nomic Co-operation and Development countries [2]. The costs
associated with treating type 2 diabetes and, in particular, asso-
ciated complications make up a substantial proportion of overall
health-care spending. For example, the American Diabetes Asso-
ciation estimated that in the United States in 2007, approxi-
mately US$1 in every US$5 spent on health care was spent on
caring for someone with diabetes and that US$1 in every US$10
spent on health care was directly attributable to the disease [3].
In South Korea, mortality due to diabetes has increased more
than threefold since the 1980s, from 5.3 per 100,000 in 1983 to
18.4 per 100,000 in 2001 [4], making it the fourth leading cause
of mortality [5]. Within the same time frame (1983–2001), South
Korea experienced a ﬁvefold decrease in the mortality rate from
infectious diseases, increased urbanization, a ﬁvefold increase in
economic output, and substantial lifestyle and dietary changes
including an increase in animal protein and fat intake. Such
changes are thought to be a major contributing factor in the
increasing prevalence of diabetes in South Korea. This is particu-
larly evident in the elderly, with prevalence rates in the popula-
tion aged >60 years reported to be 18% in males and 21% in
females [6]. Moreover, a study by Yoon et al. [7] reported that
diabetes is associated with the highest burden of disease in terms
of total disability-adjusted life-years in both men and women,
surpassing other illness groups including cardiovascular disease
(CVD) and cancer. Recent studies also indicate that a signiﬁcant
proportion of patients with type 2 diabetes in Korea are managed
suboptimally in terms of diabetes-associated risk factors. Yun
et al. [8] investigated the management of cardiovascular risk
factors in patients with type 2 diabetes in an urban area of South
Korea; the management and follow-up of blood pressure, low-
density lipoprotein (LDL) cholesterol, and microalbuminuria
testing was variable. This ﬁnding was pertinent given that CVD
is the leading cause of death in patients with type 2 diabetes.
The Physician’s Routine Evaluation of Safety and Efﬁcacy
of NovoMix® 30 Therapy (PRESENT) study was a 6-month,
single-arm, open-label, observational study conducted in 15 dif-
ferent countries, including South Korea [9]. Patients with type 2
diabetes inadequately controlled on their current therapy, which
included oral antidiabetic drugs (OADs), insulin, OAD plus
insulin, or dietary modiﬁcation, were switched to biphasic insulin
aspart 30 (BIAsp 30) either as monotherapy or in combination
with OADs. BIAsp 30 is an insulin analog that consists of a
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short-acting soluble component (30%) and a long-acting
protamine-crystallized insulin aspart (70%). Randomized, con-
trolled clinical trials have shown that BIAsp 30 improves glyce-
mic control versus baseline and lowers the long-term rate of
hypoglycemic events compared with biphasic human insulin (HI)
30 [10,11]. The PRESENT study was an evaluation of BIAsp 30
within routine clinical practice. Results from a subgroup analysis
of the South Korean PRESENT study population receiving HI at
baseline show that 6 months after switching to BIAsp 30 treat-
ment, glycosylated hemoglobin (HbA1c) was reduced by 0.82%
points (P < 0.001) from baseline. All hypoglycemic events (major
and minor) were reduced from 494 to 188 events per 100 patient
years (P < 0.001). These beneﬁts were accompanied by a slight
increase in body mass index (BMI) of 0.18 kg/m2 (P < 0.001)
(Novo Nordisk data on ﬁle [12]).
The aim of this cost-effectiveness analysis was to estimate the
long-term clinical and cost outcomes associated with switching
patients poorly controlled on HI to BIAsp 30 in South Korea
based on the data from the PRESENT study.
Methods
Model
The IMS CORE Diabetes Model, a published and validated
computer simulation model, was used to estimate the long-term
cost-effectiveness of switching to BIAsp 30 from HI (for a
detailed description of the methodology of the model, see Palmer
et al. [13]). In summary, the model is a nonproduct-speciﬁc
policy analysis tool that takes into account intensive or conven-
tional insulin therapy, oral hypoglycemic medications, screening
and treatment strategies for microvascular complications, treat-
ment strategies for end-stage complications, and multifactorial
interventions. Disease progression through the model is based on
a series of 15 interdependent submodels that simulate progres-
sion of disease-related complications. The 15 interdependent
submodels estimate complication probabilities for: angina, myo-
cardial infarction, congestive heart failure, stroke, peripheral
vascular disease, diabetic retinopathy, macula edema, cataract,
hypoglycemia, ketoacidosis, lactic acidosis, nephropathy, neur-
opathy, foot ulcer and amputation, and nonspeciﬁc mortality.
Each submodel uses time, state, and diabetes type-dependent
probabilities derived from published sources. Validation of the
model has been performed, both against the data sources used
and external longitudinal studies [14].
Treatment Effects
Treatment effects applied in the simulation included the change
from baseline in HbA1c, hypoglycemic event rates (major and
minor), and BMI observed in the South Korean subgroup analy-
sis of PRESENT (n = 1321). Consequently, patients receiving
concomitant OADs and those receiving HI were included for the
analysis. Reductions in HbA1c were modeled as an initial decline
followed by a natural progression over time as observed in the
United Kingdom Prospective Diabetes Study (UKPDS) [15].
Recorded changes in BMI and hypoglycemic event rates (in
terms of events per 100 patient years) were also applied for the
simulations.
Simulated Cohort
A hypothetical cohort of 1000 patients was generated within the
model. The baseline demographics, characteristics, risk factors,
and comorbidities were derived from the South Korean
PRESENT subgroup and from published studies in comparable
populations where necessary [4,16–22]. A complete list of base-
line patient demographics, characteristics, and comorbidities are
shown in Table 1.
Costs and Perspective
A third-party payer perspective was adopted for the analysis,
incorporating the direct costs of treatment, patient management,
and diabetes-related complication costs. Primary cost collection
research was performed by the authors where published data
were unavailable. Diabetes-related complication costs were
obtained using a cost questionnaire that was sent to 54 South
Korean clinicians (Table 2). The participating clinicians included
clinic and hospital-based endocrinologists (n = 10) and other
specialists managing patients with complications including car-
diologists (n = 7), nephrologists (n = 7), neurologists (n = 5), sur-
geons (n = 6), ophthalmologists (n = 6), and internists (n = 13)
from metropolitan areas of South Korea.
All costs were accounted in 2007 South Korean Won (KRW;
US$1 = KRW936.53). Prices of HI and BIAsp 30 were obtained
from IMS data. The costs of self-monitoring blood glucose strips
Table 1 Baseline patient demographics and complications
Mean (SD) Source
Patient demographics
Baseline age (years) 57.93 (13.64) PRESENT
Duration of diabetes (years) 11.02 (7.17) PRESENT
Percentage male (%) 45.7 PRESENT
Baseline risk factors
HbA1c (%) 8.82 (1.61) PRESENT
Systolic blood pressure (mm Hg) 139.1 (21.9) [16]
Total cholesterol (mg/dl) 201.6 (41.3) [16]
HDL (mg/dl) 52 (13.1) [16]
LDL (mg/dl) 119.5 (34.2) [16]
Triglyceride (mg/dl) 158.6 (116.6) [16]
Body mass index (kg/m2) 24.57 (3.21) PRESENT
Racial characteristics
Proportion white 0 Assumed
Proportion black 0 Assumed
Proportion Hispanic 0 Assumed
Proportion Native American 0 Assumed
Proportion Asian/Paciﬁc Islander 1 Assumed
Baseline cardiovascular complications
Proportion with myocardial infarction 0.04 [17]
Proportion with angina 0.017 [22]
Proportion with peripheral vascular disease 0.011 [19]
Proportion with stroke 0.048 PRESENT
Proportion with congestive heart failure 0.13 PRESENT
Proportion with atrial ﬁbrillation 0.005 [20]
Proportion with left ventricular hypertrophy 0.017 [20]
Baseline renal complications
Proportion with microalbuminuria 0.397 [21]
Proportion with gross proteinuria 0.19 PRESENT
Proportion with end-stage renal disease 0 Assumed
Baseline eye complications
Proportion with background diabetic
retinopathy
0.397 [31]
Proportion with proliferative diabetic
retinopathy
0.088 [31]
Proportion with severe vision loss 0 Assumed
Proportion with macular edema 0.081 [31]
Proportion with cataract 0.043 [22]
Baseline foot ulcer complications
Proportion with uninfected ulcer 0.036 PRESENT
Proportion with infected ulcer 0 Assumed
Proportion with healed ulcer 0 Assumed
Proportion with history of amputation 0 Assumed
Baseline neuropathy
Proportion with neuropathy 0.376 PRESENT
HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipopro-
tein; PRESENT, Physician’s Routine Evaluation of Safety and Efﬁcacy of NovoMix® 30
Therapy; SD, standard deviation.
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and OAD treatments were excluded from the analysis, because
they were assumed not to differ between treatment arms.
Discounting and Time Horizon
In the base-case analysis, future costs and clinical beneﬁts were
discounted at a rate of 5% per annum, in accordance with
Korean Health Insurance Review Agency guidelines (http://
www.ispor.org/PEguidelines/index.asp). The analysis was per-
formed over a time horizon of 30 years to capture the incidence
of all diabetes-related complications and associated costs over
patient lifetimes.
Sensitivity Analyses
A series of sensitivity analyses were performed to address the
impact of several key parameters on ﬁnal outcomes. The simu-
lations performed in the sensitivity analysis were: 1) treatment
efﬁcacy—simulations were performed assuming an HbA1c
improvement of half that was observed in the PRESENT trial, no
HbA1c reduction, and no reduction in hypoglycemic events; 2)
cost of complications—the costs associated with complications
were increased by 20% and decreased by 20% to address uncer-
tainty around cost collection data; 3) time horizon—simulations
were performed using time horizons of 5, 10, and 20 years to
assess outcomes over periods shorter than patient lifetimes; and
4) discount rates—a discount rate of 0% was applied.
Probabilistic sensitivity analysis (PSA) was also performed to
address uncertainty at the patient and treatment effect level. PSA
was done by sampling from the distributions generated around
cohort characteristics (age, duration of diabetes, HbA1c, systolic
blood pressure, total cholesterol, high-density lipoprotein, LDL,
triglycerides, and BMI) and treatment effects (changes in HbA1c
and BMI). Measures of dispersion were only incorporated where
data were available.
Statistical Methodology
A simulated cohort of 1000 patients was run through the model
1000 times for each simulation (base-case and sensitivity analy-
sis) using a nonparametric bootstrapping approach, and mean
values and standard deviations were generated [23]. One thou-
sand mean values (each of 1000 patients) of incremental costs
and incremental effectiveness in terms of quality-adjusted life
expectancy (QALE) were plotted (scatter plots) on a cost-
effectiveness plane. Acceptability curves were generated based on
the percentage of points on the scatter plots below a range of
willingness-to-pay thresholds.
Results
Clinical Outcomes
In the base-case analysis, switching uncontrolled patients to
BIAsp 30 was associated with a mean increase in life expectancy
of 0.15  0.18 years compared with continued HI treatment
(Table 3) and a mean increase in QALE of 0.30  0.12 quality-
adjusted life-years (QALYs) per patient. Patients treated with
BIAsp 30 were projected to have a lower overall incidence of
diabetes-related complications and a slower onset of complica-
tions. In the BIAsp 30 group, patients remained free of compli-
cations for 0.73 years on average, compared with 0.63 years for
Table 2 Diabetes-related complication and management costs based on
clinician survey in Korea in 2007
KRW
Management costs
Annual cost of statins 129,456
Annual cost of aspirin 18,300
Annual cost of microalbuminuria screening 32,050
Annual cost of macroalbuminuria screening 24,460
Annual cost of eye screening 56,310
Annual cost of foot screening 171,480
Direct costs of CVD complications
Cost of myocardial infarction, year of event 3,080,290
Cost of myocardial infarction, subsequent years 1,092,070
Cost of angina, year of onset 1,750,000
Cost of angina, subsequent years 626,540
Cost of coronary heart failure, year of onset 1,295,830
Cost of coronary heart failure, subsequent years 797,500
Cost of stroke, year of event 2,808,700
Cost of stroke, subsequent years 880,000
Cost of stroke, death within 30 days of event 6,111,110
Direct costs of renal complications
Cost of hemodialysis, ﬁrst year 5,277,780
Cost of hemodialysis, subsequent years 4,444,440
Cost of peritoneal dialysis, ﬁrst year 5,277,780
Cost of peritoneal dialysis, subsequent years 4,444,440
Cost of renal transplant, year of procedure 18,571,430
Cost of renal transplant, subsequent years 3,214,290
Direct costs of acute events
Cost of major hypoglycemic event 440,000
Cost of ketoacidosis event 1,703,130
Cost of lactic acidosis event 1,113,330
Direct costs of eye disease
Cost of laser treatment procedure 400,000
Cost of cataract operation, year of procedure 1,200,000
Direct costs of other complications
Cost of amputation event 2,961,540
Cost of prosthesis after amputation event 2,533,330
ACE, angiotensin-converting enzyme;CVD, cardiovascular disease; KRW, South KoreanWon.
Table 3 Clinical and economic outcomes
BIAsp 30 HI D
Life expectancy (years) 8.62 (0.13) 8.47 (0.13) 0.15 (0.18)
Quality-adjusted life expectancy (QALYs) 5.68 (0.09) 5.38 (0.09) 0.30 (0.12)
Total costs 12,214,835 (259,424) 10,437,982 (253,378) 1,776,855 (358,623)
Treatment costs 5,315,031 2,371,708 2,943,323
Management costs 2,012,114 1,980,240 31,874
Cost of complications (KRW)
Cardiovascular complications 3,386,327 3,493,907 -107,580
Nephropathy 922,096 1,168,179 -246,083
Ulcer, amputation, and neuropathy 338,353 335,160 3,193
Retinopathy 111,446 119,245 -7,799
Hypoglycemia 114,634 954,239 -839,605
Incremental cost-effectiveness ratio (KRW per QALY gained) 5,915,198
Values shown are means with standard deviations in parentheses.
BIAsp 30, biphasic insulin aspart 30; HI, human insulin; KRW, South Korean Won; QALY, quality-adjusted life-year.
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HI. Among the most notable delays in onset were those for
neuropathy and gross proteinuria, which were both delayed by
0.44 years by switching to BIAsp 30 (for neuropathy, 5.43 years
to onset with BIAsp 30 vs. 4.99 years with HI; for gross pro-
teinuria, 9.79 years for BIAsp 30 vs. 9.35 years for HI). In terms
of the incidence of diabetes-related complications, BIAsp 30
reduced the overall incidence of neuropathy and renal, cardio-
vascular, ophthalmologic, and diabetic foot complications. The
most pronounced reductions were observed in the incidence of
neuropathy (3.54%) and gross proteinuria (2.86%). Treatment
with BIAsp 30 led to a twofold reduction in the incidence of
major hypoglycemic events and an eightfold reduction in the
incidence of minor hypoglycemic events.
Cost Outcomes
Mean total direct costs associated with switching to BIAsp 30
were KRW1,777,323 per patient higher than treatment with HI
(Table 3). The higher costs associated with BIAsp 30 treatment
were mainly due to the 55% increase in drug acquisition costs.
This is partly due to the fact that BIAsp 30-treated patients have
a higher life expectancy than those treated with HI. As a result,
BIAsp 30-treated patients will undergo treatment for a longer
period of time and will likely have higher management costs
associated with, for example, blood glucose monitoring and
screening programs.
Treatment with BIAsp 30 was associated with a decrease in
costs of most complications. Reductions in the costs of CVD,
renal, and ophthalmologic complications were KRW107,580,
KRW246,083, and KRW7799, respectively. In addition, the
notable reduction in hypoglycemic events that was observed with
BIAsp 30 led to a cost reduction of KRW839,605 compared with
HI.
Cost-Effectiveness
In terms of life expectancy, the incremental cost-effectiveness
ratio (ICER) calculated for BIAsp 30 was KRW11,899,882 per
life-year gained (discounted), and the ICER based on QALE
was KRW5,916,758 per QALY gained (discounted) (Table 3).
Figure 1 shows the cost-effectiveness plane for the 1000 mean
values, each consisting of 1000 patients. The data points on the
scatter plot are located almost exclusively within the upper right-
hand quadrant, indicating that BIAsp 30 is associated with
higher cost and higher efﬁcacy compared with HI.
Figure 2 shows a cost-effectiveness acceptability curve for
BIAsp 30 versus HI, based on quality adjusted life-year out-
comes. Assuming a willingness-to-pay threshold of KRW25
million per QALY gained (less than gross domestic product per
capita on a purchasing power parity basis) [24], there is a 97.5%
chance that BIAsp 30 will be cost-effective compared with HI.
This value represents the percentage of points on the cost-
effectiveness plane that fall under the willingness-to-pay thresh-
old, based on 1000 bootstrap simulations.
Sensitivity Analysis
One-way sensitivity analysis was performed to assess the impact
of changes in efﬁcacy, complication costs, time horizon, and
discount rates. To see Table S1, see Cost-Effectiveness of Switch-
ing to Biphasic Insulin Aspart 30 from Human Insulin in Patients
with Poorly Controlled Type 2 Diabetes in South Korea Value
in Health Supporting Information at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH12s3_White.asp. The
outcomes of the simulation were most sensitive to alterations in
projected efﬁcacy. Assuming that BIAsp 30 treatment resulted in
no improvement in hypoglycemic events, the ICER (cost per
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Figure 1 Incremental cost and quality-adjusted
life expectancy for biphasic insulin aspart 30
versus human insulin.
0
10
20
30
40
50
60
70
80
90
100
0 20 40 60 80 100
Willingness-to-pay threshold (million KRW)
P
er
ce
n
ta
g
e 
ac
ce
p
ta
b
ili
ty
 (
%
)
Figure 2 Cost-effectiveness acceptability curve for biphasic insulin aspart 30
versus human insulin.
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QALY gained) increased to KRW19,248,486, and the difference
in QALE decreased to 0.137 QALYs. Likewise, if the improve-
ment in terms of the projected reduction in HbA1c was halved or
no reduction at all was projected, the ICER for BIAsp 30 was
KRW8,037,980 per QALY gained and KRW11,911,421 per
QALY gained, respectively; this was also accompanied by a
reduction in the improvement in QALE to 0.231 and 0.137
QALYs. Increasing and decreasing complication costs by 20%
had a minimal effect on the ICER. If complication costs were
increased by 20%, the ICER was KRW5,119,207 per QALY
gained. Decreasing complication costs by 20% resulted in an
ICER of KRW6,714,304 per QALY gained. The ICER was also
sensitive to time horizon and increased from KRW5,916,758 per
QALY gained to 8,587,115 per QALY gained as the time horizon
of the simulation was reduced from 30 years to 5 years. Never-
theless, performing the simulation over a time horizon of 5 years
fails to capture any long-term beneﬁts associated with switching
to BIAsp 30, such as the avoidance of end-stage complications.
Altering the discount rate to 0% had a minimal impact on the
ICER.
One-way and two-way sensitivity analyses were performed by
varying the projected reduction in both hypoglycemic events and
HbA1c associated with switching to BIAsp 30 (Figure 3). Sensi-
tivity analyses were performed using projected improvements of
0.2, 0.4, 0.6, and 0.8 times the magnitude of the improvements
observed in the base-case. As projected, clinical improvements
associated with switching to BIAsp 30 decreased and the ICER
increased, however, the increases observed in the ICER were not
linear. In terms of the magnitude of the impact that the projected
improvements had on the ICER, as expected, small reductions in
the observed improvements had aminimal impact on the ICER. By
contrast, in situations where the efﬁcacy of BIAsp 30 was signiﬁ-
cantly reduced, small changes in efﬁcacy resulted in large changes
in the ICER. For example, if the reduction in hypoglycemic events
was assumed to be the same as in the base-case, an accompanying
reduction in HbA1c from the base-case improvement value
(-0.82%points) to 0.8 times (-0.66%points) was associatedwith
an increase in the ICER fromKRW5,916,758 per QALY gained to
KRW6,692,074 per QALY gained. A decrease in HbA1c from 0.4
times (-0.33% points) to 0.2 times (-0.16% points) the reduction
of the base case (-0.82% points), while assuming the full reduc-
tion in hypoglycemia, resulted in an increase in the ICER from
KRW8,556,935 per QALY gained to KRW9,995,336 per QALY
gained.
Incorporating second-order uncertainty into the simulation
led to an increase in the ICER to approximately KRW10,147,797
per QALY gained and a reduction in the improvement in QALE to
just 0.17 QALYs. PSA was also performed to address uncertainty,
and the cost-effectiveness plane from the PSA is shown in Figure 4.
The dispersion of points was greater when PSA was performed,
however, the shape was more elliptical compared with the base-
case because of the relatively few input parameters that incorpo-
rated uncertainty (due to data limitations) and the high inﬂuence
of HbA1c in the model, which was varied probabilistically.
Discussion
Data from the PRESENT study have been reported elsewhere
[9,25,26] and have shown that BIAsp 30 is an efﬁcacious treat-
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Figure 4 Cost-effectiveness plane for biphasic
insulin aspart 30 versus human insulin when
probabilistic sensitivity analysis was performed.
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ment in patients with poorly controlled type 2 diabetes in a
multinational setting. Subgroup analyses from the South Korean
cohort reafﬁrms this. At 6 months, South Korean patients had a
mean HbA1c reduction of 0.82% points and exhibited a greater
than twofold reduction in hypoglycemic events after therapy
conversion to BIAsp 30. Results from this analysis show that
switching to BIAsp 30 treatment improves projected life expect-
ancy by 0.15  0.18 years and QALE by 0.30  0.12 QALYs.
Moreover, BIAsp 30 reduced the incidence of, and delayed the
onset of, type 2 diabetes-related complications. The PRESENT
study was designed as a single-arm, open-label, observational
study, and patients that participated in the trial who had failed to
achieve satisfactory glycemic control on previous medications
were permitted to continue taking concomitant medications. As
such, the clinical results may have been open to the inﬂuence of a
number of confounding factors. The strengths and weaknesses of
observational study data have been reported extensively elsewhere
[27]. From the perspective of health outcomes research, observa-
tional trials arguably capture real-world clinical end points.
The total direct cost associated with switching patients to
BIAsp 30 was approximately KRW1.8 million higher per patient
than continuing with standard HI treatment. Most of the
increase was attributable to increased treatment and patient
management costs, partly as a result of increased life expectancy
on BIAsp 30. In the base-case analysis, the ICER was approxi-
mately KRW5.9 million, substantially below a recently used cost-
effectiveness threshold value of KRW25 million [28]. An
extended discussion of pharmaceutical cost-effectiveness initia-
tives in South Korea can be found elsewhere [29]. Sensitivity
analysis revealed efﬁcacy parameters and time horizon to be key
drivers of direct costs, although the ICER remained within the
range of cost-effectiveness in almost all scenarios.
This is one of the ﬁrst studies to assess the cost-effectiveness of
a type 2 diabetes intervention within the South Korean setting,
and as such, involved the collation of valuable information,
particularly diabetes complication cost data. This information
may be useful for future cost-effectiveness analyses in the Korean
setting.
Many of the calculations that are performed in the model are
based on data from landmark epidemiological studies and clini-
cal trials, such as the Framingham Heart Study and the UKPDS.
Both studies were performed in predominantly white populations
and, therefore, may not necessarily provide representative risks
for Asian populations. For example, diabetes is known to be an
independent risk factor for coronary heart disease (CHD), and a
recent study investigated the accuracy of Framingham CHD pre-
diction scores, reporting that the risks of CHD events were
systematically overestimated in some ethnic groups [30]. Never-
theless, there is currently a paucity of relevant epidemiological
data from Asian populations, in particular, data suitable for the
South Korean setting. It was necessary to assume the applicabil-
ity of the landmark trials and studies to the South Korean setting
and to use published Korean data to deﬁne the baseline preva-
lence of complications that were not recorded in PRESENT.
A number of caveats associated with computer simulation
modeling should also be noted. One of the principal limitations
of long-term outcome models is that this technique uses short-
term data to project outcomes over time frames of up to 30 years.
This process is associated with inherent uncertainties; however,
in the absence of long-term data, computer simulation modeling
represents one of the best tools available to predict long-term
economic and clinical outcomes. Moreover, it is not viable to
conduct clinical studies over such a long time period.
The results presented here suggest that BIAsp 30 is an efﬁca-
cious intervention in terms of reducing HbA1c levels and the
incidence of hypoglycemic events in South Koreans with type 2
diabetes who are poorly controlled on HI. BIAsp 30 treatment
was associated with higher pharmacy and patient management
costs compared with HI, at an ICER of KRW5,916,758 per
QALY gained. BIAsp 30 is likely to be a cost-effective interven-
tion for patients poorly controlled on HI.
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